Abiraterone acetate, 1000 mg, once daily is approved for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and high-risk metastatic castration-sensitive prostate cancer (mCSPC) in combination with prednisone, 5 mg, orally twice daily or once daily, respectively.1 However, the ideal dose of prednisone combined with abiraterone acetate is not known. In this issue of JAMA Oncology, Attard and colleagues2 report on the safety results of a phase 2 study of abiraterone acetate in combination with 4 different glucocorticoid regimens in the mCRPC setting.
Swami U, Pal SK, Agarwal N. Ideal Glucocorticoid Regimen With Abiraterone Acetate: Options and Challenges. JAMA Oncol. Published online June 27, 20195(8):1167–1169. doi:10.1001/jamaoncol.2019.1008
Browse and subscribe to JAMA Network podcasts!
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: